Octavio Espinoza, the chief financial officer of Ligand Pharmaceuticals (NASDAQ:LGND), completed a block sale of 3,057 shares of company common stock on March 11, 2026, at $225.00 per share, producing proceeds of $687,825. The transaction occurred while the shares were trading close to their 52-week peak of $227.92, following a 92% gain over the previous 12 months.
Filings with the Securities and Exchange Commission show that Espinoza concurrently exercised stock options to acquire 2,405 shares at an exercise price of $92.65, a move the filing values at $222,823. Both the sale and the option exercise were executed under a pre-arranged trading plan that Espinoza adopted on November 19, 2025. After completing the sale, Espinoza directly holds 21,010 shares of Ligand common stock.
These insider transactions were disclosed on a Form 4 submitted to the SEC. The timing of the sale places it near the company’s 52-week high and follows a year in which the stock has appreciated sharply. According to a market valuation note cited in the filing, InvestingPro analysis currently indicates that LGND is trading above its Fair Value. A Pro Research Report on LGND is available alongside coverage for more than 1,400 other U.S. equities for investors seeking additional valuation context.
Ligand’s recent operating results provide context for both the share-price momentum and the analyst commentary. The company reported fourth-quarter 2025 earnings per share of $2.02, beating analyst expectations of $1.49. Quarterly revenue came in at $59.7 million, ahead of the $55.6 million analysts had forecast. For the full year, Ligand posted $268 million in revenue, with core revenue of $240 million, and full-year adjusted earnings per share of $8.13.
Following the results, several brokerages reinforced constructive ratings. Oppenheimer increased its price target on Ligand to $277 from $275 while maintaining an Outperform rating and citing a favorable outlook on the company’s royalty revenue. Ligand’s fourth-quarter royalty revenue was reported at $50.5 million, consistent with Oppenheimer’s estimates. Stifel reiterated a Buy rating and kept a $230 price target on the shares. Collectively, these analyst assessments and the company’s reported results underline a period of solid financial performance and sustained positive sentiment from equity analysts.
The SEC filing and the company’s reported earnings form the factual basis for the disclosed insider activity. The filing specifies the trades were carried out under a pre-set plan and documents Espinoza’s post-transaction ownership. Investors and market participants can consult the referenced valuation analysis and the Pro Research report for further detail on relative valuation.